373 related articles for article (PubMed ID: 29170783)
1. Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.
Meier-Menches SM; Gerner C; Berger W; Hartinger CG; Keppler BK
Chem Soc Rev; 2018 Feb; 47(3):909-928. PubMed ID: 29170783
[TBL] [Abstract][Full Text] [Related]
2. Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates.
Riedl CA; Flocke LS; Hejl M; Roller A; Klose MH; Jakupec MA; Kandioller W; Keppler BK
Inorg Chem; 2017 Jan; 56(1):528-541. PubMed ID: 27996251
[TBL] [Abstract][Full Text] [Related]
3. Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles.
Novak MS; Büchel GE; Keppler BK; Jakupec MA
J Biol Inorg Chem; 2016 Jun; 21(3):347-56. PubMed ID: 26961253
[TBL] [Abstract][Full Text] [Related]
4. Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles.
Büchel GE; Gavriluta A; Novak M; Meier SM; Jakupec MA; Cuzan O; Turta C; Tommasino JB; Jeanneau E; Novitchi G; Luneau D; Arion VB
Inorg Chem; 2013 Jun; 52(11):6273-85. PubMed ID: 23659478
[TBL] [Abstract][Full Text] [Related]
5. Highly Cytotoxic Osmium(II) Compounds and Their Ruthenium(II) Analogues Targeting Ovarian Carcinoma Cell Lines and Evading Cisplatin Resistance Mechanisms.
Hildebrandt J; Häfner N; Kritsch D; Görls H; Dürst M; Runnebaum IB; Weigand W
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563367
[TBL] [Abstract][Full Text] [Related]
6. Polynuclear ruthenium, osmium and gold complexes. The quest for innovative anticancer chemotherapeutics.
Hartinger CG; Phillips AD; Nazarov AA
Curr Top Med Chem; 2011; 11(21):2688-702. PubMed ID: 22039871
[TBL] [Abstract][Full Text] [Related]
7. Development of anticancer agents: wizardry with osmium.
Hanif M; Babak MV; Hartinger CG
Drug Discov Today; 2014 Oct; 19(10):1640-8. PubMed ID: 24955838
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, structure and anticancer properties of new biotin- and morpholine-functionalized ruthenium and osmium half-sandwich complexes.
Marloye M; Inam H; Moore CJ; Debaille V; Pritchard JR; Gelbcke M; Meyer F; Dufrasne F; Berger G
J Biol Inorg Chem; 2021 Aug; 26(5):535-549. PubMed ID: 34173882
[TBL] [Abstract][Full Text] [Related]
9. Varying the metal to ethacrynic acid ratio in ruthenium(ii)/osmium(ii)-p-cymene conjugates.
Păunescu E; Soudani M; Clavel CM; Dyson PJ
J Inorg Biochem; 2017 Oct; 175():198-207. PubMed ID: 28779652
[TBL] [Abstract][Full Text] [Related]
10. cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339.
Büchel GE; Kossatz S; Sadique A; Rapta P; Zalibera M; Bucinsky L; Komorovsky S; Telser J; Eppinger J; Reiner T; Arion VB
Dalton Trans; 2017 Sep; 46(35):11925-11941. PubMed ID: 28850133
[TBL] [Abstract][Full Text] [Related]
11. Design of Ru-arene Complexes for Antitumor Drugs.
Su W; Li Y; Li P
Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
[TBL] [Abstract][Full Text] [Related]
12. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents.
Peacock AF; Sadler PJ
Chem Asian J; 2008 Nov; 3(11):1890-9. PubMed ID: 18712745
[TBL] [Abstract][Full Text] [Related]
13. In-Cell Activation of Organo-Osmium(II) Anticancer Complexes.
Needham RJ; Sanchez-Cano C; Zhang X; Romero-Canelón I; Habtemariam A; Cooper MS; Meszaros L; Clarkson GJ; Blower PJ; Sadler PJ
Angew Chem Int Ed Engl; 2017 Jan; 56(4):1017-1020. PubMed ID: 28000997
[TBL] [Abstract][Full Text] [Related]
14. Bypassing the Resistance Mechanisms of the Tumor Ecosystem by Targeting the Endoplasmic Reticulum Stress Pathway Using Ruthenium- and Osmium-Based Organometallic Compounds: An Exciting Long-Term Collaboration with Dr. Michel Pfeffer.
Gaiddon C; Gross I; Meng X; Sidhoum M; Mellitzer G; Romain B; Delhorme JB; Venkatasamy A; Jung AC; Pfeffer M
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500819
[TBL] [Abstract][Full Text] [Related]
15. Cancer cell cytotoxicity of cyclometalated compounds obtained with osmium(II) complexes.
Boff B; Gaiddon C; Pfeffer M
Inorg Chem; 2013 Mar; 52(5):2705-15. PubMed ID: 23427955
[TBL] [Abstract][Full Text] [Related]
16. Fluorescent organometallic rhodium(I) and ruthenium(II) metallodrugs with 4-ethylthio-1,8-naphthalimide ligands: Antiproliferative effects, cellular uptake and DNA-interaction.
Streciwilk W; Terenzi A; Cheng X; Hager L; Dabiri Y; Prochnow P; Bandow JE; Wölfl S; Keppler BK; Ott I
Eur J Med Chem; 2018 Aug; 156():148-161. PubMed ID: 30006161
[TBL] [Abstract][Full Text] [Related]
17. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells.
Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V
Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087
[TBL] [Abstract][Full Text] [Related]
18. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
[TBL] [Abstract][Full Text] [Related]
19. Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands.
Zhang Y; Zheng W; Luo Q; Zhao Y; Zhang E; Liu S; Wang F
Dalton Trans; 2015 Aug; 44(29):13100-11. PubMed ID: 26106875
[TBL] [Abstract][Full Text] [Related]
20. Precious metal carborane polymer nanoparticles: characterisation of micellar formulations and anticancer activity.
Barry NP; Pitto-Barry A; Romero-Canelón I; Tran J; Soldevila-Barreda JJ; Hands-Portman I; Smith CJ; Kirby N; Dove AP; O'Reilly RK; Sadler PJ
Faraday Discuss; 2014; 175():229-40. PubMed ID: 25270092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
